Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Gold Prices Drop Amid Iran Peace Talk Uncertainty and Stronger Dollar 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
